» Articles » PMID: 37607461

Lipoprotein(a) and the Pooled Cohort Equations for ASCVD Risk Prediction: The Multi-Ethnic Study of Atherosclerosis

Overview
Journal Atherosclerosis
Publisher Elsevier
Date 2023 Aug 22
PMID 37607461
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) but is not included in the Pooled Cohort Equations (PCE). We aimed to assess how well the PCE predict 10-year event rates in individuals with elevated Lp(a), and whether the addition of Lp(a) improves risk prediction.

Methods: We compared observed versus PCE-predicted 10-year ASCVD event rates, stratified by Lp(a) level and ASCVD risk category using Poisson regression, and evaluated the association between Lp(a) > 50 mg/dL and ASCVD risk using Cox proportional hazards models in the Multi-Ethnic Study of Atherosclerosis (MESA). We evaluated the C-index and net reclassification improvement (NRI) with addition of Lp(a) to the PCE.

Results: The study population included 6639 individuals (20%, n = 1325 with elevated Lp(a)). The PCE accurately predicted 10-year event rates for individuals with elevated Lp(a) with observed event rates falling within predicted limits. Elevated Lp(a) was associated with increased risk of CVD events overall (HR 1.27, 95% CI 1.00-1.60), particularly in low (HR 2.45, 95% CI 1.40-4.31), and high-risk (HR 1.41, 95% CI 1.02-1.96) individuals. Continuous NRI (95% CI) with the addition of Lp(a) to the PCE for CVD was 0.0963 (0.0158-0.1953) overall, and 0.2999 (0.0876, 0.5525) among low-risk individuals.

Conclusions: The PCE performs well for event rate prediction in individuals with elevated Lp(a). However, Lp(a) is associated with increased CVD risk, and the addition of Lp(a) to the PCE improves risk prediction, particularly among low-risk individuals. These results lend support for increasing use of Lp(a) testing for risk assessment.

Citing Articles

Lipoprotein(a) Atherosclerotic Cardiovascular Disease Risk Score Development and Prediction in Primary Prevention From Real-World Data.

Fan W, Wu C, Wong N Circ Genom Precis Med. 2025; 18(1):e004631.

PMID: 39851061 PMC: 11849056. DOI: 10.1161/CIRCGEN.124.004631.


A Narrative Review of the Role of Blood Biomarkers in the Risk Prediction of Cardiovascular Diseases.

Garady L, Soota A, Shouche Y, Chandrachari K, K V S, Shankar P Cureus. 2025; 16(12):e74899.

PMID: 39742176 PMC: 11688159. DOI: 10.7759/cureus.74899.


Strategies for management of patients with elevated lipoprotein(a).

Ellberg C, Bhatia H Curr Opin Lipidol. 2024; 35(5):234-240.

PMID: 39145610 PMC: 11387124. DOI: 10.1097/MOL.0000000000000950.


Lipoprotein(a) Levels in Disaggregated Racial and Ethnic Subgroups Across Atherosclerotic Cardiovascular Disease Risk Levels.

Dudum R, Huang Q, Yan X, Fonseca M, Jose P, Sarraju A JACC Adv. 2024; 3(6):100940.

PMID: 38938854 PMC: 11198068. DOI: 10.1016/j.jacadv.2024.100940.


Lipoprotein(a), Residual Cardiovascular Risk, and the Search for Targeted Therapy.

Blaha M, Bhatia H J Am Coll Cardiol. 2024; 83(16):1540-1542.

PMID: 38537912 PMC: 11216951. DOI: 10.1016/j.jacc.2024.03.370.

References
1.
Willeit P, Ridker P, Nestel P, Simes J, Tonkin A, Pedersen T . Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018; 392(10155):1311-1320. DOI: 10.1016/S0140-6736(18)31652-0. View

2.
Wilsgaard T, Mathiesen E, Patwardhan A, Rowe M, Schirmer H, Lochen M . Clinically significant novel biomarkers for prediction of first ever myocardial infarction: the Tromsø Study. Circ Cardiovasc Genet. 2015; 8(2):363-71. DOI: 10.1161/CIRCGENETICS.113.000630. View

3.
Mehta A, Vasquez N, Ayers C, Patel J, Hooda A, Khera A . Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk. J Am Coll Cardiol. 2022; 79(8):757-768. PMC: 10966924. DOI: 10.1016/j.jacc.2021.11.058. View

4.
Willeit P, Kiechl S, Kronenberg F, Witztum J, Santer P, Mayr M . Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014; 64(9):851-60. DOI: 10.1016/j.jacc.2014.03.061. View

5.
FRIEDEWALD W, Levy R, Fredrickson D . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. View